Literature DB >> 30642983

TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.

Tara S Abraham1, John C Flickinger1, Scott A Waldman1, Adam E Snook2.   

Abstract

Characterizing self-tolerance mechanisms and their failure is critical to understand immune homeostasis, cancer immunity, and autoimmunity. However, examination of self-tolerance mechanisms has relied primarily on transgenic mice expressing TCRs targeting well-characterized, but nonphysiologic, model Ags, such as OVA and hemagglutinin. Identifying TCRs directed against bona fide self-antigens is made difficult by the extraordinary diversity of TCRs and the low prevalence of Ag-specific clones (<10-100 naive cells per organism), limiting dissection of tolerance mechanisms restricting immunity to self-proteins. In this study, we isolated and characterized TCRs recognizing the intestinal epithelial cell receptor and colorectal cancer Ag GUCY2C to establish a model to study self-antigen-specific tolerance mechanisms. GUCY2C-specific CD4+ effector T cells were isolated from immunized, nontolerant Gucy2c -/- mice. Next-generation sequencing identified GUCY2C-specific TCRs, which were engineered into CD4+ T cells in vitro to confirm TCR recognition of GUCY2C. Further, the generation of "retrogenic" mice by reconstitution with TCR-transduced hematopoietic stem cells resulted in normal CD4+ T cell development, responsiveness to immunization, and GUCY2C-induced tolerance in recipient mice, recapitulating observations in conventional models. This retrogenic model can be employed to define self-tolerance mechanisms restricting T and B cell responses to GUCY2C to optimize colorectal cancer immunotherapy without autoimmunity.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30642983      PMCID: PMC6363846          DOI: 10.4049/jimmunol.1801206

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Generation of T Cell Receptor Retrogenic Mice.

Authors:  Yuelin Kong; Yi Jing; Maria Bettini
Journal:  Curr Protoc Immunol       Date:  2019-05-15

2.  GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Authors:  Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-02-02

3.  Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.

Authors:  Adam E Snook; Trevor R Baybutt; Bo Xiang; Tara S Abraham; John C Flickinger; Terry Hyslop; Tingting Zhan; Walter K Kraft; Takami Sato; Scott A Waldman
Journal:  J Immunother Cancer       Date:  2019-04-23       Impact factor: 13.751

4.  T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.

Authors:  John C Flickinger; Jagmohan Singh; Yanki Yarman; Robert D Carlson; Joshua R Barton; Scott A Waldman; Adam E Snook
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 8.786

5.  Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.

Authors:  John C Flickinger; Jagmohan Singh; Robert Carlson; Elinor Leong; Trevor R Baybutt; Joshua Barton; Ellen Caparosa; Amanda Pattison; Jeffrey A Rappaport; Jamin Roh; Tingting Zhan; Babar Bashir; Scott A Waldman; Adam E Snook
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 12.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.